Prometheus Biosciences Stock Prediction & Price:
According to 11 analysts’ stock projections for Prometheus Biosciences Inc. (RXDX:NSD), the company’s average 12-month target price is USD 61.60. The typical analyst recommendation forRXDX stock is a Strong Buy.
Prometheus Biosciences Inc.’s stock analysis by Stock Target Advisor is Slightly Bearish and is based on 2 positive signals and 4 negative signals. The stock price of Prometheus Biosciences Inc. was USD 36.06 at the most recent closing.
The stock price of Prometheus Biosciences Inc. changed by -13.19% over the previous week, -26.75% over the previous month, and +20.52% over the previous year.
Prometheus Biosciences Stock-News:
On Wednesday, Prometheus Biosciences released data on encouraging findings from 2 inflammatory disease tests for one of its medications.
The company examined patients with ulcerative colitis and Crohn’s disease, two types of irritable bowel illness, using its pharmaceutical drug that is known as PRA023. After 3 months of starting treatment, over half of those with Crohn’s disease and more than a quarter of those with ulcerative colitis went into remission.
In comparison to 1.5% of the placebo group, 26.5% of ulcerative colitis patients had reached remission after 12 weeks. The results beat the original Prometheus predictions for a 10%–15% betterment in symptoms. The company attributes the placebo reaction to the patient group’s severe condition.
In the Crohn’s disease test, 26% of patients experienced an endoscopic response, and 49.1% of patients went into remission. The new drug also showed a very positive indicator determining it was not just very effective in its treatment protocol, but also a very safe drug to administer.
About Prometheus Biosciences Inc. (RXDX:NSD):
Ignyta, Inc. is a precision oncology biotechnology business that finds, acquires, develops, and markets molecularly focused treatments for curing lingering illnesses.
Entrectinib, a tyrosine kinase inhibitor targeting tropomyosin receptor kinase family tyrosine kinase receptors, ROS1, and anaplastic lymphoma kinase proteins is one of the products in its pipeline.
It is undergoing Phase II and two Phase I clinical studies in molecularly defined adult patient populations for the treatment of solid tumors, as well as Phase I/Ib clinical studies The business was established in 2011 and has its corporate office in San Diego, California.
Conclusion:
RXDX stock scores 3.3 out of 10 for its fundamental analysis rating, which means the fundamentals on the stock are slightly Bearish.
